Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OFATUMUMAB vs OLAPARIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OFATUMUMAB vs OLAPARIB: Safety Overview

Metric OFATUMUMAB OLAPARIB
Total FAERS Reports 29,913 18,274
Deaths Reported 695 5,496
Death Rate 2.3% 30.1%
Hospitalizations 3,616 3,471
Average Patient Age 47.5 yrs 62.3 yrs
% Female Patients 74.9% 79.9%
FDA Approval Date N/A Aug 17, 2017
Manufacturer Novartis Pharmaceuticals Corporation AstraZeneca Pharmaceuticals LP
Route INTRAVENOUS ORAL
Marketing Status Prescription Discontinued